Uric Acid, Heart Failure Survival, and the Impact of Xanthine Oxidase Inhibition

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Increasing evidence suggests that serum uric acid (UA), a product of xanthine oxidase (XO), may be a useful marker for metabolic, hemodynamic, and functional staging in heart failure (HF) and a valid predictor of survival in HF patients. Recent data support an expanded role for UA and the XO pathway in the pathogenesis of HF, as studies have shown that an elevation in the enzymatic activity of XO can lead to increases in oxidative stress, endothelial dysfunction, and reduced myocardial function. Numerous population studies have previously reported that elevated UA levels are an independent predictor of cardiovascular mortality, and recent evidence suggests that lowering serum levels of UA may lead to improved outcomes in HF patients. The question of whether UA is only a marker rather than a causal factor in the pathogenesis of HF remains. Regardless of whether UA levels are ready for routine clinical use, either as a prognostic factor or novel therapeutic target, further prospective studies are necessary to demonstrate that routine measurement or reduction of UA levels improves outcomes in HF patients.

Original languageEnglish
Pages (from-to)179-182
Number of pages4
JournalCongestive Heart Failure
Volume18
Issue number3
DOIs
StatePublished - May 1 2012

Fingerprint

Xanthine Oxidase
Uric Acid
Heart Failure
Survival
Serum
Oxidative Stress
Hemodynamics
Prospective Studies
Mortality
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Emergency Medicine
  • Emergency

Cite this

Uric Acid, Heart Failure Survival, and the Impact of Xanthine Oxidase Inhibition. / Harzand, Arash; Tamariz, Leonardo; Hare, Joshua.

In: Congestive Heart Failure, Vol. 18, No. 3, 01.05.2012, p. 179-182.

Research output: Contribution to journalArticle

@article{abb95150f0854a9f8d421a23bba9a5c3,
title = "Uric Acid, Heart Failure Survival, and the Impact of Xanthine Oxidase Inhibition",
abstract = "Increasing evidence suggests that serum uric acid (UA), a product of xanthine oxidase (XO), may be a useful marker for metabolic, hemodynamic, and functional staging in heart failure (HF) and a valid predictor of survival in HF patients. Recent data support an expanded role for UA and the XO pathway in the pathogenesis of HF, as studies have shown that an elevation in the enzymatic activity of XO can lead to increases in oxidative stress, endothelial dysfunction, and reduced myocardial function. Numerous population studies have previously reported that elevated UA levels are an independent predictor of cardiovascular mortality, and recent evidence suggests that lowering serum levels of UA may lead to improved outcomes in HF patients. The question of whether UA is only a marker rather than a causal factor in the pathogenesis of HF remains. Regardless of whether UA levels are ready for routine clinical use, either as a prognostic factor or novel therapeutic target, further prospective studies are necessary to demonstrate that routine measurement or reduction of UA levels improves outcomes in HF patients.",
author = "Arash Harzand and Leonardo Tamariz and Joshua Hare",
year = "2012",
month = "5",
day = "1",
doi = "10.1111/j.1751-7133.2011.00262.x",
language = "English",
volume = "18",
pages = "179--182",
journal = "Congestive Heart Failure",
issn = "1527-5299",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Uric Acid, Heart Failure Survival, and the Impact of Xanthine Oxidase Inhibition

AU - Harzand, Arash

AU - Tamariz, Leonardo

AU - Hare, Joshua

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Increasing evidence suggests that serum uric acid (UA), a product of xanthine oxidase (XO), may be a useful marker for metabolic, hemodynamic, and functional staging in heart failure (HF) and a valid predictor of survival in HF patients. Recent data support an expanded role for UA and the XO pathway in the pathogenesis of HF, as studies have shown that an elevation in the enzymatic activity of XO can lead to increases in oxidative stress, endothelial dysfunction, and reduced myocardial function. Numerous population studies have previously reported that elevated UA levels are an independent predictor of cardiovascular mortality, and recent evidence suggests that lowering serum levels of UA may lead to improved outcomes in HF patients. The question of whether UA is only a marker rather than a causal factor in the pathogenesis of HF remains. Regardless of whether UA levels are ready for routine clinical use, either as a prognostic factor or novel therapeutic target, further prospective studies are necessary to demonstrate that routine measurement or reduction of UA levels improves outcomes in HF patients.

AB - Increasing evidence suggests that serum uric acid (UA), a product of xanthine oxidase (XO), may be a useful marker for metabolic, hemodynamic, and functional staging in heart failure (HF) and a valid predictor of survival in HF patients. Recent data support an expanded role for UA and the XO pathway in the pathogenesis of HF, as studies have shown that an elevation in the enzymatic activity of XO can lead to increases in oxidative stress, endothelial dysfunction, and reduced myocardial function. Numerous population studies have previously reported that elevated UA levels are an independent predictor of cardiovascular mortality, and recent evidence suggests that lowering serum levels of UA may lead to improved outcomes in HF patients. The question of whether UA is only a marker rather than a causal factor in the pathogenesis of HF remains. Regardless of whether UA levels are ready for routine clinical use, either as a prognostic factor or novel therapeutic target, further prospective studies are necessary to demonstrate that routine measurement or reduction of UA levels improves outcomes in HF patients.

UR - http://www.scopus.com/inward/record.url?scp=84861189813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861189813&partnerID=8YFLogxK

U2 - 10.1111/j.1751-7133.2011.00262.x

DO - 10.1111/j.1751-7133.2011.00262.x

M3 - Article

C2 - 22587748

AN - SCOPUS:84861189813

VL - 18

SP - 179

EP - 182

JO - Congestive Heart Failure

JF - Congestive Heart Failure

SN - 1527-5299

IS - 3

ER -